Skip to content

Total Equity at other companies

Amgen logo
AmgenAMGN
$9.19B+48.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.42B+6.9%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$138.03M+84.8%
Regenxbio logo
RegenxbioRGNX
$21.08M-92.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$21.04M-122%
Immunome logo
ImmunomeIMNM
$588.69M+91.7%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$919.03M+28.6%
Enterprise value$873.59M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's total equity?
Replimune Group (REPL) reported total equity of $210.54M in Q4 2025.
How has Replimune Group's total equity changed year-over-year?
Replimune Group's total equity decreased by 56.4% year-over-year, from $482.37M to $210.54M.
What is the long-term trend for Replimune Group's total equity?
Over 4 years (2021 to 2025), Replimune Group's total equity has grown at a -4.4% compound annual growth rate (CAGR), from $498.73M to $415.84M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.